A stable nitroxide 4-hydroxy-2,2,6,6-tetramethylpiperidine-N-osyl (Tempol) is widely used as an antioxidant in vitro and in vivo. In this study, we investigated the effects of Tempol on the growth of As4.1 juxtaglomerular cells in relation to cell cycle and cell death. Tempol dose-dependently decreased the growth of As4.1 cells with an IC 50 of ~1 mM at 48 h. DNA flow cytometry analysis and BrdU staining indicated that Tempol induced S phase arrest, which is accompanied by a downregulation of cyclin A. Tempol also induced apoptotic cell death, which was accompanied by the loss of mitochondrial membrane potential (MMP; ∆Ψm), an activation of caspase-3 and cleavage of poly(ADP-ribose)polymerase-1 (PARP-1). Furthermore, Tempol increased reactive oxygen species (ROS) levels, and the phosphorylation of extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK). MEK and JNK inhibitors significantly attenuated a growth inhibition in Tempol-treated As4.1 cells. In conclusion, Tempol inhibited the growth of As4.1 cells via cell cycle arrest and apoptosis. Tempol also activated ERK and JNK signaling, which was responsible for cell growth inhibition. Our present data provide useful information for the toxicological effects of Tempol in juxtaglomerular cells in relation to cell growth inhibition and cell death.
Introduction
Tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl or 4-hydroxy-tempo) is a stable piperidine nitroxide, which is widely employed in electron spin resonance spectroscopy (1) . It is also known that Tempol protects cells from oxidative damage in vitro and in vivo (2) . Several antioxidant mechanisms have been proposed to account for these protective effects. It may act as a mimic of superoxide dismutase (SOD) and it can reduce the formation of hydroxyl radicals either by scavenging superoxide anion or by reducing intracellular concentration of Fe(II) (3) . Usually, such beneficial effects are observed up to a few µM. However, the prospect of moving it from the experimental to the clinical arena has prompted more detailed studies on their possible toxicity. Much evidence suggests that Tempol impairs ferritin synthesis and Fe metabolisms, consequently leading to cell death (4) . In addition, mutagenic effects has been reported in different bacterial strains (5) . Of note, Tempol as a pro-oxidant induces the cell cycle arrest and apoptosis depending on cell types (6) . Therefore, in order to clarify these discrepancies among the different effects of Tempol, further study needs to be performed for re-evaluating its real biological functions and roles.
The mitogen-activated protein kinases (MAPKs) are a large family of serine/threonine kinases, which are major comp onents of signaling pathways in cell proliferation, differentiation, and cell death (7) . There are currently three known MAPKs: the extracellular signal-regulated kinase (ERK1/2), the c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) and the p38 (7) . Each MAPK pathway has relatively different upstream activators and specific substrates (7) . Accumulating evidence demonstrates that JNK and p38 are strongly activated by ROS and/or a mild oxidative shift of the intracellular thiol/ disulfide-redox state, leading to apoptosis (8, 9) . ROS are also known to induce ERK phosphorylation and activate ERK pathway (10) . In most instances, ERK activation has been by the prosurvival functions rather than proapoptotic effects (11) .
Tempol protects cells from oxidative damage in vivo (2) Annexin V staining. Apoptosis was determined by staining cells with Annexin V-fluorescein isothiocyanate (FITC) (Ex/Em=488/519 nm) as previously described (14) . In brief, 1ⅹ10 6 cells were incubated with the designated doses of Tempol with or without MAPK inhibitors for 48 h. Cells were washed twice with cold PBS and then resuspended in 500 µl of binding buffer (10 mM HEPES/NaOH pH 7.4, 140 mM NaCl, 2.5 mM CaCl 2 ) at a concentration of 1ⅹ10 6 cells/ml. Five microliters of Annexin V-FITC (Molecular Probe, USA) was then added to these cells, which were analyzed with a FACStar flow cytometer (Becton-Dickinson).
Quantification of caspase-3 activity. The activity of caspase-3 was assessed using caspase-3 Colorimetric Assay kits (R&D Systems, Inc.) according to the manufacturer's instructions. In brief, 1ⅹ10 6 cells were incubated with the designated doses of Tempol for 48 h then washed in PBS and suspended 5 volumes of lysis buffer (20 mM HEPES pH 7.9, 20% glycerol, 200 mM KCl, 0.5 mM EDTA, 0.5% NP40). Protein concentration was determined by the Bradford method. Supernatant samples containing 100 µg total proteins were added to DEVD-PNA in 96-well microtiter plates (Nunc) and incubated at 37˚C for 1 h. Optical density was measured at 405 nm using a microplate reader (Spectra MAX 340, Molecular Devices Co.). Each plate contained multiple wells of a given experimental condition and multiple control wells.
Measurement of MMP (∆Ψm).
The MMP (∆Ψm) was measured using the Rhodamine 123 fluorescent dye (Ex/Em=485/535 nm), which preferentially enters mitochondria (13) . In brief, 1ⅹ10 Detection of intracellular ROS and GSH. Intracellular ROS were detected by means of an oxidation-sensitive fluorescent probe dye 2',7'-dichlorodihydrofluorescein diacetate (H2DCFDA, Invitrogen Molecular Probes, OR; Ex/Em=495/529 nm) and dihydroethidium (DHE, Invitrogen Molecular Probes, OR; Ex/Em=510/580 nm) (15) . Cellular GSH levels were analyzed suing 5-chloromethylfluorescein diacetate (CMFDA, Invitrogen Molecular Probes; Ex/Em=522/595 nm) (15) . ROS and GSH levels were expressed as mean fluorescence intensity (MFI), which was calculated by CellQuest software (Becton-Dickinson).
Statistics. The results represent the mean of at least three independent experiments (mean ± SD). The data were analyzed using Instat software (GraphPad Prism4, San Diego, CA). The Student's t-test or one-way analysis of variance (ANOVA) with post hoc analysis using Tukey's multiple comparison test was used for parametric data. Statistical significance was defined as p<0.05.
Results

Effects of Tempol on the growth of As4.1 cells.
We examined the effects of Tempol on the growth of As4.1 cells by trypan blue cell counting. Treatment with 0.5-10 mM Tempol significantly decreased the population of cells for 48 h in a dose-dependent manner (Fig. 1A) . When the growth of As4.1 cells was also investigated by an MTT assay, dose-dependent reduction of cell growth was observed in As4.1 cells with an IC 50 of 1 mM following treatment with Tempol for 48 h (Fig. 1B) .
Effects of Tempol on intracellular ROS and GSH levels in As4.1 cells. Next, we determined whether Tempol changes the intracellular ROS and GSH levels. As shown in Fig. 2A , ROS (DCF) levels were increased in Tempol-treated As4.1 cells. Red fluorescence derived from DHE, which reflected O 2
•-accumulation, was also increased in As4.1 cells treated with Tempol at 48 h (Fig. 2B) . In relation to GSH, Tempol increased GSH depleted cell number in As4.1 cells (Fig. 2C) .
Effects of Tempol on the cell cycle distribution in As4.1 cells.
We examined the effect of Tempol on the cell cycle distribution in live As4.1 cells without sub-G1 DNA content cells. As shown in Fig. 3A , DNA flow cytometric analysis indicated that treatment with 0.5-2 mM Tempol markedly induced an S phase arrest of the cell cycle at 48 h. However, relatively higher dose of Tempol did not alter the cell cycle distribution (Fig. 3A) . To confirm the Tempol-induced S phase arrest in As4.1 cells, we examined BrdU incorporation assay. Consistent with the DNA flow cytometric analysis, the number of BrdU-positive cells was increased in Tempol-treated As4.1 cells (Fig. 3B) . Next, we determined the levels of S phase-related proteins. While treatment with Tempol down-regulated cyclin-dependent kinase inhibitor (CDKI) p27 and cyclin A, it up-regulated CDK2 and cyclin E expression (Fig. 3C) .
Effects of Tempol on cell death and MMP (∆Ψm) in As4.1 cells. Next, we determined whether Tempol induces cell death in As4.1 cells using Annexin V/PI staining. As shown in Fig. 4A , the proportion of Annexin V-staining cells in Tempol-treated cells was increased in a dose-dependent manner, which indicates that Tempol-induced As4.1 cell death occurred via apoptosis. In addition, treatment with Tempol augmented PI (+)/Annexin (-) staining cells, which represents necrotic cell death. Caspase-3 plays an essential role as an executioner in apoptosis (16) . Therefore, we examined whether Tempol activates caspase-3 during the induction of apoptosis in As4.1 cells. The activity of caspase-3 was significantly elevated in Tempol-treated cells as compared with the control cells (Fig. 4B) , which suggest that the activation of caspase-3 occurred in Tempol-treated cells. In regard to PARP-1 protein, which is a major substrate for executed caspases and a hallmark of apoptosis, Western blotting showed that cleaved 89 kDa moiety of PARP was increased in Tempol-treated As4.1 cells, implying that PARP-1 was degraded in Tempol-treated cells (Fig. 4C) .
To elucidate the effect of Tempol on MMP (∆Ψm) using Rhodamine 123, cells were treated with the indicated doses of Tempol for 48 h (Fig. 5) . Treatment with Tempol induced the loss of MMP (∆Ψm) in As4.1 cells in a dose-dependent manner.
To determine whether the loss of MMP (∆Ψm) cells were dead or not, we stained cells with PI to verify the disruption of the plasma membrane. As shown in Fig. 4 , many of the negative Rhodamine 123 fluorescence cells showed PI positive staining, which indicated that many cells showing the loss of MMP (∆Ψm) were considered to be dead. (Fig. 6A) . However, it did not affect that of p38 (data not shown). Next, we examined the effects of MAPK inhibitors on cell growth, cell cycle and apoptosis in Tempol-treated As4.1 cells. As shown in Fig. 6B , treatment with MEK and JNK inhibitors significantly prevented growth inhibition of As4.1 cells. While MEK inhibitor significantly decreased the percent of S phase, JNK inhibitor did not (Fig. 6C) . JNK inhibitor reduced the number of Annexin V positive staining cells ~10% in Tempol-treated cells. Treatment with each inhibitor did not affect cell growth, cell cycle and apoptosis in control cells (Fig. 6 ). •-levels in Tempol-treated As4.1 cells or -untreated control cells (Fig. 7B) . In addition, we analyzed the changes of GSH levels in As4.1 cells in the presence of Tempol and/or MEK or JNK inhibitor. Tempol increased the number of GSH depleted cells in As4.1 cells by ~30% compared with control cells at 48 h (Fig. 7C) . JNK inhibitor significantly reduced the number in Tempol-treated As4.1 cells. Neither MEK or JNK inhibitor altered GSH level in As4.1 control cells (Fig. 7C) .
Effects of MAPK inhibitors on cell growth, cell cycle and apoptosis in
Effects of MEK or JNK inhibitor on intracellular ROS and GSH levels in
Discussion
In the present study, we focused on evaluating the effects of Tempol on juxtaglomerular As4.1 cells in relation to cell growth and death. According to our results, Tempol significantly decreased the population and cell growth of As4.1 cells for 48 h in a dose-dependent manner, which was accompanied with the increase in intracellular ROS levels. Much evidence suggests that Tempol acts as an antioxidant agent at 5 mM concentration in lens epithelial cells (17) , hepatic satellite cells (18) , and endothelial cells (19) . In contrast, it is also reported that Tempol exhibits cytoxic effects by inducing excessive ROS at concentration as low as 1 mM in Chinese hamster ovary cells (20) , breast cancer cells (6) and human leukemia HL-60 cells (21) . Our results indicate that Tempol as a pro-oxidant inhibits cell growth in As4.1 cells. Although the mechanisms underlying ROS generation after Tempol treatment was not clearly explained, it seems that Tempol localized on mitochondria directly induces mitochondrial dysfunction, which results in excessive ROS generation (4) . Therefore, the apparent paradoxical effect of Tempol in different cells could be explained by assuming that each cell has different basal activities of mitochondria and on antioxidant enzymes.
Suppression of cell growth by Tempol can be explained in part by arrest during the cell cycle (22) . DNA flow cytometric analysis indicated that treatment with 0.5-1 mM Tempol significantly induced S phase arrest of the cell cycle at 48 h. These concentrations did not induced similar level of cell death as evidenced by Annexin V/PI staining implying that the S phase arrest by Tempol can be considered as one of the pathways to suppress the growth of As4.1 cells. Treatment with 5 and 10 mM Tempol inhibited cell growths without the change of cell cycle distribution compared to the As4.1 control cells. Thus, it is likely that >5 mM Tempol nonspecifically extended all phases of the cell cycle. The S phase arrest in Tempoltreated As4.1 cells was accompanied with the alteration of cell cycle-related proteins. Treatment with Tempol showed the down-regulation of cyclin-dependent kinase inhibitor p27, which forms complexes with CDKs and cyclins related to the progression of the G1 phase and G2/M phase, and inhibits their activity (23) . These data indirectly support the result that Tempol could induce an S phase arrest rather than a G1 phase and/or a G2/M phase arrest of the cell cycle. Among the CDKs and cyclin proteins that regulate the cell cycle, CDK2 and cyclin A are critical to the progression of S phase in the cell cycle (24) . The production of cyclin A and its complex with CDK2 enables S phase progression (25) . Tempol up-regulated the expression of CDK2 protein, but the level of cyclin A was decreased in Tempol-treated cells. However, orderly S phase progression requires the down-regulation of E2F1 activity, which is partially accomplished by CDK-mediated phosphorylation (26) . Inhibition of CDK activity during S phase results in inappropriately persistent E2F, which can cause S phase delay (26) and apoptosis (27) . Cyclin A mRNA and protein levels are known to be low before S phase, but increased significantly during S and G2/M phases (28) , which implies that the expression of cyclin A is increased during S phase. Therefore, S phase arrest in Tempol-treated As4.1 cells did not result from the shortage of cyclin A. We cannot exclude the possibility that the activity of cyclin A-CDK2 complex was decreased by Tempol treatment, consequently causing the S phase arrest.
According to our result, the intracellular ROS including O 2
•-were increased in parallel with depletion of GSH in Tempol-treated As4.1 cells. Thus, it is likely that ROS formation due to Tempol may cause mitochondrial dysfunction and subsequent cytochrome c release, which lead to apoptosis (29) . Concerning apoptosis, cytochrome c forms an apoptosome that is composed of Apaf-1 and procaspase-9, resulting in the activation of caspase-9. Caspase-9 activates the effecter procaspase, including procaspase-3, to carry out the process of apoptosis (30) . Correspondingly, Tempol induced loss of MMP (∆Ψm) and activated caspase-3 in As4.1 cells. We also observed that the proportion of Annexin V-positive staining cells was similar to that of Rhodamine 123-negative staining cells. These results imply that the loss of MMP (∆Ψm) by Tempol leads to apoptosis in As4.1 cells.
Little is known about MAPK signaling in Tempol-induced growth inhibition. We found that Tempol activated ERK and JNK signaling in As4.1 cells. Treatment with MEK inhibitor, which presumably inhibited ERK signaling, prevented the In summary, Tempol dose-dependently inhibited the growth of As4.1 cells via inducing S phase arrest and triggering cell death. Tempol also activated ERK and JNK signaling, which was responsible for cell cycle and cell death, respectively. Our present data provide useful information for the toxicological effects of Tempol in juxtaglomerular cells in relation to cell growth inhibition and cell death.
